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CIZ1-F, an alternatively spliced variant of the DNA replication protein CIZ1 with
distinct expression and localisation, is overrepresented in early stage common
solid tumours
Dorian R.A. Swarts , Emma R. Stewart , Gillian S. Higgins, and Dawn Coverley
Department of Biology, The University of York, York, UK
ABSTRACT
CIZ1 promotes cyclin-dependent DNA replication and resides in sub-nuclear foci that are part of
the protein nuclear matrix (NM), and in RNA assemblies that are enriched at the inactive X
chromosome (Xi) in female cells. It is subjected to alternative splicing, with specific variants
implicated in adult and pediatric cancers. CIZ1-F is characterized by a frame shift that results
from splicing exons 8–12 leading to inclusion of a short alternative reading frame (ARF), excluding
the previously characterized C-terminal NM anchor domain. Here, we apply a set of novel variant-
selective molecular tools targeted to the ARF to profile the expression of CIZ1-F at both transcript
and protein levels, with focus on its relationship with the RNA-dependent and -independent
fractions of the NM. Unlike full-length CIZ1, CIZ1-F does not accumulate at Xi, though like full-
length CIZ1 it does resist extraction with DNase. Notably, CIZ1-F is sensitive to RNase identifying it
as part of the RNA-fraction of the NM. In quiescent cells CIZ1-F transcript expression is suppressed
and CIZ1-F protein is excluded from the nucleus, with re-expression not observed until the second
cell cycle after exit from quiescence. Importantly, CIZ1-F is over-expressed in common solid
tumors including colon and breast, pronounced in early stage but not highly-proliferative late
stage tumors. Moreover, expression was significantly higher in hormone receptor negative breast
tumors than receptor positive tumors. Together these data show that CIZ1-F is expressed in
proliferating cells in an unusual cell cycle-dependent manner, and suggest that it may have
potential as a tumor biomarker.
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Introduction
CDKN1A interacting zinc finger protein 1 (CIZ1)
is subject to extensive alternative splicing to yield
multiple transcript variants [1–5]. Functional ana-
lysis of discrete protein fragments has identified
domains and regulatory sites in the N-terminal
half of the protein that are involved in DNA repli-
cation [6,7] and interaction with cell cycle regula-
tors [7], (Figure 1(a,b)). Separate sequences in the
C-terminus of CIZ1 support interaction with
nuclear structures, identifying a salt and DNase-
resistant nuclear matrix (NM) interaction domain
[8], which may restrict its function to specific sub-
nuclear locations. Recently, we and others showed
that CIZ1 localizes to the inactive X chromosome
(Xi) and is required to ensure retention of Xist
long non-coding RNA (lncRNA) at Xi in fibro-
blasts [9,10]. Alternative splicing affects both the
replication domain (RD) and NM anchor domain
(AD) of CIZ1, and several splicing events have
been implicated in cancer, including mutation dri-
ven exclusion of exon 4 (CIZ1-Δ4) in Ewing’s
Tumor cell lines [2] and exclusion of 24 nucleo-
tides of exon 14 in lung cancer (CIZ1-B) [5]. A
unique splice-junction epitope from CIZ1-B is a
circulating biomarker for patients with small cell
and non-small cell lung cancer [5,11]. CIZ1 has
also been reported to be involved in the develop-
ment of breast cancer [12], the most common type
of cancer in women [13]. Alternative splicing of
CIZ1 is implicated in other chronic diseases
including upregulation of a form in which part of
exon 8 is excluded (CIZ1-S) in Alzheimer’s disease
[3], and in cervical dystonia where mutations in an
exonic splicing enhancer may affect splicing pat-
terns [14].
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Despite functional studies that link full-length
murine CIZ1 and embryonic variant murine CIZ1
(ECIZ1) with DNA replication [6,7], little is
known about the function of other variants.
Alternative splicing of CIZ1 may have important
consequences for the cell and is known to affect
the sub-nuclear localization of the protein
(Supplementary Table 1). For example, exclusion
of exon 4 changes the sub-nuclear distribution of
CIZ1 from focal to diffuse [2]. Thus alternative
splicing of CIZ1 may influence the spatial organi-
zation of DNA replication, and suggests that some
Figure 1. Human CIZ1 and variant CIZ1-F.
(A) Exonic sequence in messenger RNA of full-length and CIZ1-F, with location of primers (pri) and Taqman probes indicated.
Sequences are provided in Supplementary Table 2. Lines indicate the location of sequences that encode the protein domains
illustrated in (B). Four alternative exon 1s are indicated; CIZ1-F has been detected in combination with exons 1b, 1c, and 1d. (B) Full-
length and CIZ1-F protein showing annotated protein domains including glutamine-rich regions (Q), nuclear localization signals
(NLS), zinc finger domains (ZF), matrin-3 domain (MH3), and acidic domain (AcD). Characterized functional domains and interaction
sites for full-length CIZ1 are also shown, including replication domain (RD) which contains all sequences required for replication
activity [6], and anchor domain (AD) which contains sequences that are sufficient to mediate attachment to the nuclear matrix [8].
The CIZ1-F specific sequence, encoded by an alternative reading frame (ARF) of exon 12–13, is highlighted in light blue. Also shown
are the location of K/RXL cyclin-binding motifs implicated in replication [7] (‘C’), LXXLL ER-interaction motifs (asterisks), and
sequences reported for full-length CIZ1 to interact with CDC6 [18], cyclin-dependent kinase 2 (CDK2) [15], cyclins A and E [7],
dynein light chain (DYNLL1) [15], estrogen-receptor (ER) [12], enhancer of rudimentary homolog (ERH) [42], p21 [16], and YAP [17].
Note that several of these interactions were discovered in mouse CIZ1, and that the reported interaction between ER and CIZ1 is not
via a domain that includes LXXLL [12]. X-axis shows amino acid number. (C) Amino acid sequence of the CIZ1-F protein, with the
sequence specified by its ARF bold and underlined. The peptides in red and purple were used to generate CIZ1-F-specific antibodies.
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CIZ1 splice variants have the potency to act as
dominant-negative controllers of other var-
iants [2].
We previously designed an exon-junction
microarray that identified a number of novel var-
iants of CIZ1, including one common cancer-asso-
ciated CIZ1-variant characterized by a continuous
deletion of part of exon 8, exon 9–11 and part of
exon 12, here referred to as CIZ1-F (Figure 1(a))
[1]. CIZ1-F was initially identified in Ewing’s
Tumor cell lines and found to be overexpressed
in primary lung tumors but not matched normal
tissues [1]. Here, we characterize CIZ1-F mRNA
and protein expression patterns by exploiting a
short unique peptide encoded by expression of
an alternative reading frame (ARF) of exon
12–13. We show that CIZ1-F is specifically
expressed in G1 phase following mitosis but not
G1 phase following quiescence. Despite lacking the
C-terminal NM-attachment domain [8] and sev-
eral protein interaction sites that are important for
replication function, CIZ1-F resists extraction with
DNase1. It is however sensitive to RNase, which
contrasts with the behavior of full-length CIZ1.
Most importantly, CIZ1-F is overexpressed in
early stage primary human tumors and is asso-
ciated with ER-negative status in breast tumors.
Results
Human CIZ1-F is characterized by an 1181 base
pair deletion (c1038_2218del1181 in reference
sequence NM_012127.2), which excludes part of
exons 8 and 12 and all of exons 9–11 (Figure 1(a),
Supplementary Figure 1(a)). The exon 8–12 junc-
tion causes a frame-shift in the CIZ1 reading
frame, leading to a premature translational stop
codon in exon 13, despite the presence of down-
stream exons in CIZ1-F mRNA (Figure 1(a)).
CIZ1-F protein therefore lacks previously charac-
terized functional domains, including the MH3-
domain which anchors CIZ1 to the NM [8], and
cyclin-binding motifs through which CIZ1 inter-
acts with cyclin A, and which are essential for its
DNA replication activity (Figure 1(b)) [6,7]. Other
characterized sites of interaction with CDK2,
p21cip1 and YAP are also excluded [15–17], while
interaction with CDC6 [18], ERα [12], and dynein
light chain [15] might be retained. The interaction
sites of the CIZ1 binding factors PDRG1 [19],
SH3BP4 [20], and TCF4 [21] are not yet charac-
terized. Importantly, the ARF created by the 8–12
junction encodes 37 amino acids of unique
sequence not present in other forms of CIZ1, or
in other proteins, and results in inclusion of two
additional LXXLL estrogen receptor (ER)-interac-
tion motifs (Figure 1(b,c)) [22]. Thus CIZ1-F tran-
script appears to encode a 315 amino acid protein
with a unique C-terminal end. To study CIZ1-F
mRNA expression we designed a CIZ1-F junction-
specific gene expression probe (Supplementary
Table 2, Supplementary Figure 1(b-c)). Initially,
CIZ1-F mRNA levels were measured by qRT-
PCR in a set of cell lines (Supplementary
Figure 1(d)), revealing variable levels, with high
expression in bladder and cervical cancer lines EJ
and HeLa, as well as in breast cancer cell lines
MCF-7, BT474 and MDA-MB-231. Evaluation of
cultured tumor-derived cell lines showed that
CIZ1-F transcript is elevated in MCF7 breast can-
cer cells compared to normal MCF-10A breast
cells (Supplementary Figure 1(d)), and is in fact
one of the main CIZ1 PCR-products
(Supplementary Figure 1(a)), identifying MCF7
cells as a model cell line to study the function of
CIZ1-F in cell proliferation. However, despite the
reported functional interaction between CIZ1 and
ERα [12], we were unable to detect a reproducible
effect of estrogen on the expression of CIZ1 or
CIZ1-F transcript in MCF7 cells (Supplementary
Figure 1(e)).
CIZ1-F protein is part of the RNA-dependent NM
In order to confirm that CIZ1-F transcript encodes a
protein we generated an affinity-purified anti-peptide
antibody against sequences in the unique C-terminal
ARF of predicted CIZ1-F protein (Figure 1(c)).
Specificity of the antibody was confirmed using ecto-
pically expressed EGFP-full-length CIZ1 and EGFP-
CIZ1-F for western blot and immunofluorescence
applications (Supplementary Figure 2(a-b)). Further
confirmation of the specificity of our CIZ1-F antibody
was obtained using peptide blocking, which yielded
two CIZ1-F-specific products of approximately 42kD
and 71kD in total cell lysates (Supplementary Figure 2
(c)). The 42kD monomeric CIZ1-F product is larger
than the predictedmolecularweight of CIZ1-F (34kD)
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Figure 2. Nuclear CIZ1-F resists extraction of chromatin but not RNA.
(A-B) CIZ1-F does not localize to the inactive X chromosome (Xi). Immunofluorescencewith amonoclonal antibody for a peptide located in the
CIZ1 anchor domain (AD; green) shows both diffuse nuclear expression and specific localization to a region previously shown to be the Xi [9].
Immunofluorescencewith purified antibody raised to the CIZ1-F ARF (red) shows absence of Xi-localization. DNA is stainedwith Hoechst33258
(blue). Nuclei in white boxes are enlarged in (B). (C) Overview of nuclear matrix (NM) extraction procedure. MCF-7 cells were serially extracted
with 1) detergent-containing cytoskeletal buffer (CSK), 2) detergent-containing CSK supplementedwith 0.5MNaCl (mock extraction), 3) DNase
1, or 4) RNase, or 5) both enzymes (see methods). (D) MCF-7 cells subjected to the treatments described under (C) were counterstained with
Hoechst33258 to control for removal of chromatin (blue), and probed with purified polyclonal anti-CIZ1-F or replication domain (CIZ1-RD)
antibody 1794 (red). CIZ1-RD resists all treatments, while CIZ1-F is sensitive to extraction of RNA, and is also dramatically revealed by removal of
chromatin. Bar is 10 microns. (E) Quantification of the fluorescence intensities in (D), shown after subtraction of background signal and
expressed relative to detergent treated cells. Number of cells quantified ≥ 70 per condition. Numbers refer to the treatment conditions listed
above. (F) Enhanced and enlarged images of the indicated nuclei i-iv from (D), showing detergent and DNase-resistant nuclear fractions. (G)
Interpretation of the data showing the dependency of CIZ1-F on RNA for nuclear retention, compared to full resistance of CIZ1-RD.
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but in agreement with the mobility of EGFP-CIZ1-F
after subtraction of EGFP (45kD; Supplementary
Figure 2(a)).
Since full-length CIZ1 localizes to the Xi and
interacts with Xist lncRNA, we first determined
the relationship between CIZ1-F and the Xi in
MCF-7 cells. Full-length CIZ1, detected by a
monoclonal antibody to a C-terminal epitope,
clearly localizes to the Xi in MCF-7 cells, though
in line with reports that Xi in breast cancer-
derived cells is a less discrete (compact) entity
than in ‘normal’ cells [23] Xi staining is markedly
irregular, and also accompanied by the nucleus
wide signal that is typical of CIZ1 [9]. In contrast,
CIZ1-F shows a different pattern including both
nuclear and cytoplasmic foci, but no enrichment at
Xi (Figure 2(a-b)). We next examined the relation-
ship of full-length CIZ1 and CIZ1-F with the NM.
Full-length CIZ1 is part of the core protein NM
(resistant to extraction with DNase and RNase), as
evident by immunodetection of endogenous CIZ1
with RD-specific antibodies (Figure 2(c-f)).
Analysis of attachment to this core protein NM
can be recapitulated using EGFP-full-length CIZ1
and derived fragments, allowing the domain
responsible for attachment to the NM to be
located at the C-terminal end, and classified as
‘anchor domain’ or AD [8]. AD is missing from
CIZ1-F, which would therefore not be expected to
resist extraction. Importantly, under identical con-
ditions to those used to profile endogenous CIZ1,
the extraction profile for CIZ1-F indicates attach-
ment to the RNA component of the NM (RNA-
protein NM) because it resists extraction with
DNase, but not when used in conjunction with
RNase (Figure 2(c-f)). Notably, direct comparison
of immunofluorescence signal in nuclei at different
stages in the extraction process shows that the
majority of the CIZ1-F epitope in the nucleus is
in fact masked by chromatin (Figure 2(e)). The
signal seen before extraction appears to be not
the same population as that revealed when chro-
matin is removed, because pre-extraction signal is
lost in mock treated nuclei and only revealed if
DNase is also included in the reaction (Figure 2
(e)). Again, despite the reported association
between ERα and CIZ1 [12], we did not observe
co-localization of CIZ1-F with nuclear ERα in
immuno-detection experiments (Supplementary
Figure 2(d)).
In conclusion, CIZ1-F resists extraction of chro-
matin and is therefore a NM protein, however it is
not part of the core protein NM like full-length
CIZ1 as it can be fully extracted by digestion of
nuclear RNA, in the presence or absence of co-
extraction of DNA, identifying it as part of the
RNA-protein NM (Figure 2(g)). The differential
extraction profiles of full-length CIZ1 and CIZ1-
F epitopes suggest that they may have distinct
functions within the NM.
CIZ1-F expression in cycling and quiescent cells
We next focused on CIZ1-F expression in cycling
and quiescent cell populations, since CIZ1-F retains
most regions involved in DNA-replication (Figure 1
(b)). In detergent-treated cell populations, endoge-
neous CIZ1-F protein expression patterns changed
on entry to quiescence, switching from nuclear loca-
lization in cycling cells, to nuclear exclusion with
cytoplasmic signal at confluence, to nearly undetect-
able in quiescence (Figure 3(a-b)). Importantly,
when quiescent cell populations were subjected to
full NM-extraction, all signal was lost when cells
were treated with DNase, demonstrating that quies-
cent cell populations do not retain any CIZ1-F on the
NM (Figure 3(c)).
CIZ1-F transcript levels were also assessed in
cycling, contact-inhibited and serum-deprived
cells, and compared to amplicons in CIZ1-RD
and CIZ1-AD (Figure 3(d-e)). Overall, CIZ1-F
transcript is approximately 50-fold lower than
‘total’ CIZ1 mRNA in cycling cells, which is
broadly consistent with the frequency of expressed
sequence tags in NCBI UniGene (accessed 03/03/
2018), where 11 of 875 sequences (all from can-
cers) are CIZ1-F. CIZ1-RD and CIZ1-AD levels
remain relatively stable during proliferative
growth, and slightly increase during growth rate
decline caused by serum starvation. However,
CIZ1-F mRNA expression fell dramatically as pro-
liferation rate dropped (Figure 3(d);
Supplementary Figure 3(a)), and recovered again
upon addition of fresh serum. In contrast, contact-
inhibited normal fetal lung fibroblast MRC5 cells
did not resume proliferation or restore CIZ1-F
CELL CYCLE 5
Figure 3. CIZ1-F transcript is suppressed and CIZ1-F protein is excluded from the nuclear matrix in quiescent cells.
(A) Immunodetection of CIZ1-F in cycling (day 2), confluent (day 4) and quiescent (day 7 with medium change) populations of MCF-7
cells, after washing with detergent-cytoskeletal buffer to remove soluble protein. Enlarged images of example cells are shown and
DAPI-stained images (left) show cell nuclei in the same fields. Bar is 10 microns. (B) Quantification of the average immunofluores-
cence signal of cells depicted in (A) after subtraction of background. Abbreviations: Cycl, cycling; Confl, confluent; Qsct, quiescent. (C)
NM-extraction of quiescent MCF-7 cell populations showing no CIZ1-F on the NM after treatment with DNase. For details on the
method see Figure 2(a). (D) Transcript levels in MCF-7 breast epithelial carcinoma cells at the indicated number of days post-plating,
measured by quantitative RT-PCR (qPCR). A parallel culture that received regular changes of media (indicated as ‘MC’), harvested at
11 d, is shown for comparison. Histograms show the mean of three technical replicates ± SEM of a representative experiment
(experiments were repeated at least 3 times). Data is expressed as relative quantification (RQ) after normalization to ACTB and CYPA,
and is calibrated to levels at day 2. Cell counts at the time of harvesting are provided ± SEM (black dotted line; average of three
counts expressed as proportion of a confluent population). Right, comparison between replication domain (CIZ1-RD), anchor domain
(CIZ1-AD) and CIZ1-F in MCF-7 cells at day 2 ± SEM, with no normalization to show relative levels. (E) As in (D) for MRC5 normal fetal
lung fibroblast cells. Right, comparison between CIZ1-RD, CIZ1-AD and CIZ1-F at day 2. SEM for three technical replicates is shown.
Primer and probe sequences are in Supplementary Table 2.
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expression when boosted with serum (Figure 3(e)).
This suggests that stable contact-induced growth
arrest suppresses expression of CIZ1-F. In the
same MCF-7 cell populations we observed addi-
tional effects on CIZ1 alternative splicing, most
notably increased CIZ1-S (Supplementary
Figure 3(a)) an isoform reported to be upregulated
in Alzheimer’s disease (Supplementary Table 1),
and changes in CIZ1-Δ4 (Supplementary Figure 3
(b)) [2,3]. Together the data show that CIZ1-F
mRNA and protein are expressed in proliferating
cells and inhibited by both serum-deprivation-
induced proliferation arrest (MCF-7), and con-
tact-inhibition-induced proliferation arrest
(MRC5).
CIZ1-F mRNA is expressed in G1 following mitosis
(M-G1) but not G1 following quiescence (Q-G1)
To understand better the role of CIZ1-F in prolifera-
tion we analyzed its cell cycle expression profile. In
order to generate synchronized populations, serum-
deprived MCF-7 cells were released back into cycle in
the presence of fresh serum and the nucleotide analog
EdU (Figure 4(a)). The frequency of EdU-positive
cells indicates that the population passes through S-
phase between 10 and 20 h after exiting quiescence,
peaking at 16 h (49% of nuclei; Figure 4(a)), and this is
preceded as expected, by an increase in expression of
cyclin EmRNA. However, CIZ1-F transcript does not
begin to increase until after the majority of cells have
passed through S-phase, recovering only at 31 h
(Figure 4(a)). In contrast,CIZ1ADandRDexpression
remains relatively stable. When MCF-7 cells were
exposed to the DNA synthesis inhibitors aphidicolin
or thymidine, or arrested in mitosis by nocodazole
upon release from quiescence, CIZ1-F expression
was strongly suppressed compared to uninhibited
cells (Figure 4(b)). Similar results were obtained with
MRC5 cell populations treated with thymidine or
nocodazole (Figure 4(c)). Thus CIZ1-F mRNA levels
do not accumulate in either S-phase or mitosis and
CIZ1-F is not expressed in Q-G1. However, when
MCF7 cells were released from arrest with nocodazole
in the M-phase following quiescence, CIZ1-F mRNA
was expressed within 2 h, which is at least 4 h before
cyclin E rises (Figure 4(d)). Thus, CIZ1-F mRNA is
expressed in early G1 phase in the second cell cycle
following release from quiescence, or M-G1
(Figure 4(e)).
CIZ1-F mRNA expression in primary tumors and
cancer cell lines
To confirm that CIZ1-F is overrepresented in cancer
tissue, and to extend our analysis of lung tumors [1],
we analyzed CIZ1 mRNA in colon and breast can-
cer. Almost without exception colon cancer samples
expressed elevated CIZ1-F compared to matched
normal control tissue (P < 0.001, Related-Samples
Wilcoxon Signed Rank Test; Figure 5(a); see
Supplementary Figure 4 for individual sample
data), and surprisingly the highest levels were in
early stage tumors (P = 0.017 for early versus late
stage, Mann-Whitney U-test). In contrast CIZ1-RD
does not increase as dramatically in early stages, nor
diminish significantly at later stages (P = 0.44 for the
same comparison, Mann-Whitney U-test; Figure 5
(a)). Thus the data indicate upregulation of CIZ1-F
specifically in early stage colon cancer. Similar
results were obtained with breast tumors with
higher CIZ1-F expression in tumor tissue compared
to normal breast tissues (P = 0.016, Mann-Whitney
U-test), whereas expression of CIZ1-RD was not
significantly different (Figure 5(b); see
Supplementary Figure 5 for individual data) [1].
Again CIZ1-F levels were most elevated in early
stage tumors (P = 0.006 when compared to normal
tissues, Mann-Whitney U-test). Thus the profile of
CIZ1-F expression across tumor stage is similar for
both breast cancer and colon cancer, and further
preliminary analysis of lung and urinary bladder
cancers returned similar trends (Supplementary
Figure 6), suggesting that the stage profile may be
common to other tumor types.
When grouped by tumor grade rather than
stage, the greatest elevation was at lowest grade
for colon cancer (Figure 5(c)), but for breast can-
cer CIZ1-F levels increased with grade (P = 0.029,
Kruskall-Wallis Test; Figure 5(d)). This is not sur-
prising however since, in this series, most low-
grade breast cancers were high-stage, and vice
versa (see Figure 5(d)).
To evaluate the relationship with proliferation,
the transcript level of the proliferation marker
MKI67 was measured in the same breast and
colon samples (Figure 5). For colon, although
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Figure 4. CIZ1-F transcript is expressed in G1-phase.
(a) Quantitative RT-PCR showing CIZ1-F transcript (red) in MCF-7 cells during the first cell cycle following release from contact-inhibition and
serum-deprivation induced cell cycle arrest, relative to ACTB and CYPA housekeeping genes, and calibrated to unreleased cells. CIZ1 anchor
domain (CIZ1-AD) and replication domain (CIZ1-RD) expression (gray lines), as well as cyclin E1 (blue) are shown for comparison. Data show
means of four experiments ± SD. The percentage of cells that incorporated EdU into newly synthesized DNA during a 30 min pulse at the
indicated times is shown for comparison (black line; two biological repeats ± SD). Note that error bars for cyclin E1 are very small (range,
0.00001–0.008). Cell cycle stages (estimates based on EdU-incorporation and cyclin-expression) are indicated below. Images on the right show
EdU (purple) and total DNA (blue) before (0 h) and after (20 h) release. Bar is 10 microns. (b) CIZ1-AD, CIZ1-RD and CIZ1-F transcript in MCF-7
cells 31 h post-release from quiescence, in the presence and absence of aphidicolin (Aph), nocodazole (Noc) and thymidine (Thy), showing
mean of three biological replicates ± SEM. (c) As in (b), but for MRC5 normal lung fetal fibroblast cells. Mean RQ of three technical replicates is
expressed relative to cycling samples (± SEM). (d) As in (a), but showing release of MCF-7 cells from a 24 h nocodazole-arrest applied 16 h after
release from quiescence. Synchronization strategy is indicated above the graph. Graph shows transcript levels (mean of three technical
replicates ± SEM), at the indicated hours after release from arrest, with cell cycle stage (based on cyclin E expression) illustrated below. Right,
control sample without nocodazole (40 h post-release from quiescence). (e) Schematic summarizing CIZ1-RD, CIZ1-AD and CIZ1-F mRNA
expression levels during the first cell cycle following release from cell cycle arrest (Q-G1) andmitotic arrest (M-G1). Primer and probe sequences
are in Supplementary Table 2.
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Figure 5. CIZ1-F is overexpressed in early stage human breast and colon cancer.
(a) CIZ1-F and replication domain (CIZ1-RD) expression in 24 primary colon tumors andmatched normal samples (Origene colon cancer cDNA
array HCRT103), showingmeanmRNA expression levels for the average of all matched normal tissues and the four cancer stage classifications.
CIZ1-RD andMKI67 are shown for comparison. Individual data per case can be found in Figure 4, and individual classifications and pathology
notes accesses at www.origene.com. (b) As in (a), showing 5 normal samples and 43 primary breast cancer samples from the indicated stages
(Origene breast cancer cDNA array BCRT102). Data for individual cases can be found in Figure 5. (c) As in (a) for the same 24 colon cancer
samples andmatched normal samples, showing meanmRNA expression grouped by grade. Grade 1: 50% late stage; grade 2: 38% late stage;
grade 3: 100% late stage (1 case, white bar). Late stage refers to stage III and stage IV. (d) As in (b) for the same 5 normal samples and 43
primary breast cancer samples, showingmeanmRNA expression grouped by grade. Grade 1: 100% late stage tumors; grade 2: 43% late stage
tumors; grade 3: 27% late stage tumors. Late stage refers to stage III and stage IV. Mean RQ’s to the mean CIZ1-RD-expression of normal
samples ± SEMare shown. Significant differences are indicated (NS, not significant). Primer andprobe sequences are in Supplementary Table 2.
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MKI67 and CIZ1-F levels correlated closely when
the matched normal tissues were included in the
analysis (P = 0.0020; Pearson Correlation), no cor-
relation was found between levels across the cancer
samples only, whereas CIZ1-RD was strongly cor-
related to MKI67 levels by both analyzes
(P ≤ 0.00043; Pearson Correlation). Although less
obvious for breast tumors, again no significant cor-
relation across the full set for CIZ1-F and MKI67
could be identified (P = 0.058; Pearson
Correlation), compared to correlation with RD
(P ≤ 0.0050; Pearson Correlation). When perform-
ing linear regression with both CIZ1-RD and CIZ1-
F in colon or breast samples, only CIZ1-RD signifi-
cantly relates to MKI67 expression in all analyzes
(P ≤ 0.0050). Thus, unlike CIZ1-RD, CIZ1-F does
not mirror expression ofMKI67 and therefore does
not seem to have a simple relationship with cell
proliferation.
Interestingly, CIZ1-F levels correlated with hor-
mone receptor status in breast tumors. ER and PR
negative tumors have significantly higher CIZ1-F
transcript levels than ER or progesterone receptor
(PR) positive tumors (P = 0.005, Mann-Whitney
U-test; Figure 6(a-b)), while HER2 status was not
correlated (Figure 6(c)). This is not the case for
CIZ1-RD, arguing for a relationship between
CIZ1-F and ERα and PR in primary tumors.
Discussion
Here we demonstrate that CIZ1-F is part of the RNA-
dependent nuclear-matrix and elevated in early-stage
cancers including hormone receptor negative, but not
positive breast tumors. We show that CIZ1-F is dis-
tinct from other forms of CIZ1 and may have poten-
tial as a biomarker of early-stage disease.
CIZ1-F is part of the RNA-dependent NM and
distinct from full-length CIZ1
CIZ1 has multiple functions, both within and out-
side the context of DNA replication and the cell
cycle, and its complexity is increased by the exis-
tence of multiple splice variants (Supplementary
Table 1) [1–7,18]. We and others have shown that
CIZ1 is a NM protein, defined by its resistance to
extraction of chromatin [3,8], which suggests that
its function is connected to nuclear architecture,
possibly contributing to the spatial regulation of
nuclear processes [6–8,18,24]. Although the NM
appears to be corrupted in certain types of cancer
[25] previous work [26–28] and our own experi-
ments indicate that MCF-7 cells retain a NM
structure to some extent. In MCF-7 cells both
CIZ1-RD and CIZ1-F, as well as ERα, resist co-
extraction with chromatin, indicating the presence
of a non-chromatin stabilizing structure with
which they are associated. This is of interest
because CIZ1-F lacks the previously characterized
NM anchor domain encoded by the C-terminal
end of CIZ1. Moreover CIZ1-F is actually revealed
by removal of chromatin, suggesting that the ARF-
encoded epitope is normally in close proximity to
chromatin, and masked by it. Further distinguish-
ing CIZ1-F from full-length CIZ1 [8] is its beha-
vior in quiescent cells. Here, CIZ1-F is excluded
from the nucleus and not evident even after
removal of chromatin, suggesting that its role is
exclusively in cycling cells. Finally, though CIZ1-F
is co-extracted with the RNA fraction of the NM
(Figure 2(g)), it does not normally reside at the Xi
implying that, unlike full-length CIZ1 this is not
mediated by interaction with Xist lncRNA [9,10].
Future research should now focus on assigning a
function to CIZ1-F. Since the unique junction
sequence is a very limited target, we were not
able to achieve specific CIZ1-F knockdown using
an siRNA approach (data not shown).
Biomarker potential for early stage cancers
Previous reports have shown overexpression of
CIZ1 in colon [29,30], gallbladder [21], lung [31],
and prostate cancer [32], as well as ependymomas,
gliomas, and medulloblastomas [33], and it has
also been reported that CIZ1 knockout mice
develop leukaemias and lymphomas [9,34].
Moreover, splice variants of CIZ1 appear to have
lineage-specific functions [4] some of which are
over-represented in human tumors; notably CIZ1-
Δ4 in Ewings tumor and CIZ1-B in lung tumors
[2,5]. However, for most published analyzes it is
not clear which variants are reported on, and in
some cases transcript detection tools that are
reported to reflect CIZ1 levels may actually reflect
shifts in variant expression. Here we use validated
and specific tools to demonstrate that CIZ1-F is
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upregulated in tumors of the colon and breast, that
upregulation is most pronounced in early stage (I
and II) disease, and is not directly correlated with
proliferation. We also note that the association of
CIZ1-F with tumor grade varies between tumor
types, so although disrupted nuclear architecture
and altered NM is a common feature of poorly
differentiated and aggressive cancers [25,35], we
cannot at this stage draw a correlation with sup-
pression of CIZ1-F. In addition, our analyzes have
currently been limited to CIZ1-F mRNA levels.
Future studies should determine CIZ1-F protein
expression patterns in primary tumor samples.
Perhaps most useful is the clear correlation with
hormone receptor status of breast tumors.
Previous analysis has identified CIZ1 as an estro-
gen-responsive gene with estrogen-response ele-
ments in its promoter [12]. Moreover, the
N-terminal domain of CIZ1 protein can also inter-
act with ER, conferring hypersensitivity to estro-
gen in animal models and enhancing the
tumourigenicity of breast cancer cells [12].
Though alternative splicing was not addressed in
this study, a contribution of CIZ1-F to the cells
response to estrogen is likely because the ER inter-
action domain is partially retained in CIZ1-F, and
Figure 6. CIZ1-F expression is increased in ER-negative tumors.
Box-plots showing CIZ1 replication domain (CIZ1-RD; left), CIZ1-F (middle) and MKI67 (right) expression in (a) normal samples and
estrogen receptor (ER)-positive and -negative tumors, (b) normal samples and progesterone receptor (PR)-positive and -negative
tumors, and (c) normal samples and HER-2-positive and -negative tumors. RQ’s are expressed relative to mean CIZ1-RD-expression of
normal samples. Significant differences between subgroups are indicated (Mann Whitney U-tests; NS, not significant). Primer and
probe sequences are in Supplementary Table 2.
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it has two additional LXXLL nuclear receptor
binding motifs [22] encoded by its unique
C-terminal ARF. Contrary to published results
[12] we did not observe induction of CIZ1 upon
stimulation with estrogen for 24 h. A possible
explanation for the apparent discrepancy is that
different CIZ1 primers were used previously [12],
which may well have reported on alternative spli-
cing of CIZ1 exon 8 rather than overall levels. In
our study we detected CIZ1-RD and CIZ1-AD
amplicons in regions unrelated to exon 8 in
order to avoid this highly variable region of
CIZ1. CIZ1 binding to (PR) has not been pre-
viously studied; though it has been shown that,
in the context of NCoA-1/SRC-1, PR also requires
two LXXLL domains [36]. Thus, while we could
find no functional response to estrogen in MCF-7
cells, the presence of these domains and the cor-
relation with breast tumor receptor status supports
a relationship in vivo.
Different CIZ1 splice variants at different cell
proliferation stages
Transcript expression profile also distinguishes
CIZ1-F from other variants of CIZ1. CIZ1-F has
a distinct cell cycle-specific profile with low levels
in G0, and delayed upregulation beyond the first
cell cycle, which is at variance with the relatively
constant expression of CIZ1-RD and CIZ1-AD
amplicons (Figure 4(e)). In these studies we also
noted proliferation state dependent changes in the
CIZ1-S and CIZ1-Δ4 variants. In fact in MCF-7
cells, they seem to be inversely related to CIZ1-F,
with CIZ1-S and CIZ1-Δ4 being more highly
expressed in arrested cells (Supplementary
Figure 3). It is worth noting that both CIZ1-F
and CIZ1-S variants are the product of exon 8
splicing events, and that exon 8 splicing patterns
have been implicated in Alzheimer’s disease and
cervical dystonia [3,14].
In conclusion, this exploratory study has con-
vincingly distinguished CIZ1-F from CIZ1,
revealed association with the RNA-dependent
NM, and highlighted an unusual cell cycle expres-
sion pattern. It also supports a relationship with
estrogen responsive cancers and suggests that
CIZ1-F may have potential as a biomarker.
Materials & methods
Cell culture and tumor samples
MCF-7 breast cancer cells were cultured in mini-
mal essential medium (cat. 21090–022; Gibco, Life
Technologies, Thermo Fisher Scientific [TFS] Inc)
in the presence of 10% fetal calf serum (FCS; cat.
FB-5815 Biosera, Boussens, France) and 1X peni-
cillin-streptomycin-glutamine (PSG; cat.
10378–016; Gibco, Life Technologies, TFS Inc).
MRC5 normal lung fetal fibroblast cells were
grown in Dulbecco’s Modified Eagle Medium
(cat. 21885–025; Gibco, Life Technologies, TFS
Inc) in the presence of 10% FCS and 1X PSG.
MCF-10A normal breast cells were cultured as
previously described [37]. The cell lines were
tested and authenticated in August 2017 using
PCR-single-locus-technology (Eurofins
Medigenomix Forensik GmbH). TissueScanTM
Cancer Survey cDNA array (CSRT103; Origene)
was used to assess CIZ1-F levels in different
human cancer types. The breast cancer cDNA
array BCRT102 (Origene) was used to screen 43
breast cancer samples and 5 normal breast tissues.
The colon cancer cDNA array HCRT103
(Origene) was used to screen 24 colon cancer
samples with matched normal tissues.
Quantitative real-time PCR (qRT-PCR)
RNA was isolated using Trizol® Reagent (cat.
15596–026; Ambion RNA, Life Technologies, TFS
Inc) and reverse transcribed into cDNA using
Superscript® III First-Strand Synthesis System
(cat. 18080–051; Life Technologies, TFS Inc).
Quantitative RT-PCR was performed using SYBR
green (FastSYBR® Green Mastermix, cat. 4385612;
Applied Biosystems® [AB], TFS Inc) or Taqman
(Taqman® Fast Universal PCR Master Mix, cat.
4352042; AB, TFS Inc) reagents using the AB
StepOnePlusTM Real-Time PCR Systems (TFS
Inc). The following program was used: 95°C for
20 s, followed by 40 cycles of 95°C for 3 s and 60°C
for 30 s. Data was analyzed using the StepOne
Software v. 2.3 (AB, TFS Inc). Origene® cancer
cDNA array plates were processed with the AB
7300 system (TFS Inc) using the TaqMan®
Universal Master Mix II (cat. 4440040; AB, TFS
Inc) using the following program: 50°C for 2 min,
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95°C for 10 min, followed by 50 cycles of 95°C for
15 s and 60°C for 1 min.
Primers were designed using Primer 3 Plus
(http://primer3plus.com/), except for the ACTB
primers [5] and CYPA primers [38], which were
previously described, and cyclin D1 and cyclin E1
primers, which were retrieved from qPrimerDepot
(http://primerdepot.nci.nhi.gov). All primers are
listed in Supplementary Table 2. CIZ1-RD was
detected with primers in exon 6/7 and CIZ1-AD
with primers in exon 15/16 (Figure 1(a),
Supplementary Table 2). For the Origene cDNA
array plates, CIZ1-F was detected with primers
23–25, CIZ1-RD with primers 20–22 and MKI67
using a Taqman Assay (assay no.
Hs01032443_m1). All expression levels have been
normalized to the mean expression of ACTB and
CYPA unless stated differently.
Constructs and transfection
Human CIZ1-F was cloned from cDNA from
MCF-7 cells using PCR with DreamTaq (cat.
EP1701; TFS Inc) and T/A cloning into the
pGEM®-T Easy Vector System I (cat. A1360;
Promega) and verified by sequencing. CIZ1-F was
subsequently transferred using restriction enzymes
(PmlI and SanDI, cat. ER0361 and FD2164,
respectively; TFS Inc) into the pEGFP-C3 vector,
allowing direct comparison with full-length CIZ1,
containing all translated exons (2–17), also cloned
into pEGFP-C3 as part of a previous study [5].
Both plasmids were transiently transfected into
MCF-7 cells using the TransIT®-3T3 and
TransIT®-LT1 Transfection Kits (cat. MIR 2180
and MIR 2300, respectively; Mirus Bio LLC).
Antibodies
CIZ1-F specific antibody was made by immuniz-
ing rabbits with two peptides (Figure 1(c)) from
the unique CIZ1-F ARF-encoded peptide (Covalab
UK Ltd). Antisera from two rabbits were pooled
and immunopurified against peptide 2 (which had
no significant similarity to any other protein) and
used for Western Blot and immunofluorescence
(dilutions 1:100–1:500 and 1:50, respectively).
CIZ1-F blocking peptides were used in a 1:500
dilution. Mouse monoclonal antibody (hC221a)
against CIZ1 was raised by Fusion Antibodies
against a recombinant human CIZ1 C-terminal
fragment encoded by amino acids 678–898 in
reference sequence UniProt Q9ULV3. In addition,
purified CIZ1 1794 polyclonal antiserum [6] was
used to detect CIZ1 without discriminating CIZ1-
F. For immunofluorescence goat polyclonal anti-
mouse-AlexaFluor488 conjugate or goat polyclonal
anti-rabbit-AlexaFluor568 conjugate (cat. A11001
and A11011, respectively, Life Technologies, TFS)
were used as appropriate. For Western Blot CIZ1
exon 5 antibody (cat. HPA-020380; Sigma-
Aldrich) was used to detect CIZ1 without discri-
minating CIZ1-F. Actin (cat. A3853, Sigma
Aldrich) was used as a loading control.
Immunodetection
Protein extracts were obtained by washing cells
with cold PBS and harvesting directly into SDS
sample buffer (100 mM DTT, 2% SDS, 60 mM
Tris pH 6.8, 0.001% bromophenol blue) at 95°C
in the presence of 2 mM PMSF. Western blot was
performed as previously described [6]. Bands were
visualized using EZ-ECL (cat. 20-500-120;
Biological Industries Ltd).
For immunofluorescence, cells grown on glass cov-
erslips were transferred into PBS, washed with cytos-
keletal (CSK) buffer (containing EDTA-free protease
inhibitor tablets [cat. 05056489001; F Hoffmann-La
Roche Ltd, Sigma Aldrich] and 1 mM DTT) with or
without 0.1% Triton X-100 [39] for 30 s, then trans-
ferred to PBS and fixed for 20 min in 4% paraformal-
dehyde in PBS. Primary antibodies were incubated
for 1.5 h at 37°C and secondary antibodies for 1 h at
37°C in the dark in antibody buffer (PBS, 10 mg/ml
BSA, 0.2% SDS, 0.1% Triton X-100). Nuclei were
counterstained with DAPI (VECTASHIELD
Antifade Mounting Medium with DAPI, cat.
H-1200; Vector Laboratories).
Fluorescent image data was collected with a
Zeiss Axiovert microscope (Carl Zeiss) with a 63/
1.40 oil immersion objective and an AxioCam
camera (Carl Zeiss Vision) with Openlab software
(version 4.0.2, Improvision). Images were pro-
cessed using Adobe PhotoShop to reduce back-
ground to black and to overlay multicolor
images. Where quantitative data is derived from
the images, all capture parameters and image
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processing was identical for samples and controls
within an experiment.
Nuclear matrix extractions
Cells were fractionated as previously described
[39,40]. In brief, coverslips were washed with
detergent (0.1% Triton-X-100 in CSK), followed
by the same buffer with 0.5 M NaCl. Cells were
then incubated at 37°C for 1 h in DNase Buffer
with or without DNase I (0.5 U/µl, cat.
000000004716728001; F Hoffmann-La Roche Ltd,
Sigma Aldrich), RNase (cat. 000000011579681001;
F Hoffmann-La Roche Ltd, Sigma Aldrich) or both
nucleases in combination, then fixed for 20 min
with 8% paraformaldehyde. Vanadyl
Ribonucleoside Complex (cat. S1402S; New
England Biolabs) was added at 1:80 to all buffers
with the exception of the RNase containing treat-
ment step and its preceding wash steps. Coverslips
were counterstained with Hoechst33258
(1:100,000, cat. H3569; TFS) to verify removal of
chromatin, and immunostained as indicated.
Cell cycle synchronization
MCF-7 cells were synchronized by release from
quiescence as described [41]. Cells were grown to
confluence, then the medium was changed, and
cells cultured for a further four days without
further media changes and then released in
serum-containing medium by 1:4 splitting.
Alternatively, cells were incubated in the presence
of nocodazole (0.04 µg/ml), aphidicolin (5 µg/ml)
or thymidine (2.5 mM) for 24 h, and released from
arrest by washing twice in PBS followed by addi-
tion of fresh medium. In order to verify syn-
chrony, incorporation of EdU into newly
synthesized DNA was measured using Click-iT®
EdU Alexa Fluor® 555 (cat. C10338; Invitrogen,
Life Technologies, TFS Inc).
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics for Windows (version 21.0.0.0).
Associations between expression levels and clinical
parameters were calculated using the Mann
Whitney U-test or the Kruskall-Wallis test, and
for related samples using the Related-Samples
Wilcoxon Signed Rank Test, as indicated.
Relationships between expression levels amongst
different genes were determined using Pearson
Correlation and linear regression. All statistical
tests were two-sided and all P-values were consid-
ered significant when < 0.05. Significance levels
were indicated as follows: *, P < 0.05; **,
P < 0.01; ***, P < 0.001.
Abbreviations:
AB Applied Biosystems
AD anchor domain
ARF alternative reading frame
CIZ1 CDKN1A-interacting zinc finger protein
CSK cytoskeletal
ERα estrogen receptor alpha
FCS fetal calf serum
NM nuclear matrix
PR progesterone receptor
PSG penicillin-streptomycin-glutamine
RD replication domain
RQ relative quantity
SD standard deviation
SEM standard error of mean
qRT-PCR quantitative real-time PCR
TFS Thermo Fisher Scientific
Xi inactive X chromosome
Xist lncRNA X-inactive specific transcript long non-coding
RNA
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